secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001790340-25-000133
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q3: 86% 9-month OS in pancreatic cancer; raised $225M; cash into 2029
--------------------------------------------------------------------------------

- Reported 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib + mGnP.
- Raised $225M in financing ($175M public offering + $25M Sanofi placement + $25M private placement).
- Cash and equivalents $227.6M as of Sep 30, 2025; cash runway extended into 2029.
- Granted US composition of matter patent for atebimetinib expiring 2042, with potential term extension.
- New case studies show complete response and conversion to curative-intent surgery with atebimetinib + FOLFIRINOX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/0001790340-25-000133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/imrx-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001790340-25-000133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer